Sonja Gill
Director, Oncology Safety Combinations, Clinical Pharmacology & Safety Sciences AstraZeneca
Sonja Gill leads the Oncology Safety Combinations Team and Bone Marrow Target Organ Safety Strategy in the Clinical Pharmacology and Safety Sciences Department at AstraZeneca. Her team employs simple and advanced in vitro platforms, such as the Bone Marrow MPS, to investigate drug induced bone marrow toxicity risk for monotherapy drugs and combinations. This work informs early drug development, supports assessment of margin to risk for candidate drugs, and guides dosing strategies for successful clinical implementation of combinations across oncology programs.
Seminars
Thursday 3rd December 2026
Evidence – Human-Relevant Safety NAMs for Translational Confidence & Therapeutic Index in Oncology Drug Development
10:40 am
- Human-relevant target organ NAMS can improve translation beyond traditional in vivo models, enabling more predictive assessment of specific safety risks
- A bone marrow MPS enables assessment of drug-induced marrow suppression for oncology monotherapies and combination therapies
- Bone marrow MPS integrated with quantitative systems toxicology modelling supports reliable prediction of patient hematologic effects for oncology therapeutics
Thursday 3rd December 2026
Insight Exchange – Can We Ever Reliably Predict Safety & Efficacy Before the Clinic?
11:50 am
- Which endpoints remain hardest to predict with current models?
- How should teams balance efficacy and safety when selecting models?
- What breakthroughs are needed to improve prediction of clinical outcomes?
- Audience Q&As
